Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
The aim of the present investigation was to improve in vitro pulmonary deposition of amphotericin B (AMB) liposomal dry powder inhaler (LDPI) formulations. Liposomes with negative (AMB1) and positive (AMB2) charge were prepared by the reverse phase evaporation (REV) technique, extruded to reduce size, separated from unentrapped drug and lyophilized using an optimized cryoprotectant to achieve maximum drug retention. Lactose carrier (Sorbolac 400) in varying mass ratio with or without addition of fines (500# sieved Pharmatose 325M) in different mixing sequence were used to formulate AMB LDPI formulations. In vitro evaluation was done with twin stage impinger (TSI) for fine particle fraction. The lactose carrier containing 10% fines was found to be optimum blend at 1:6 mass ratio of liposome: lactose. The addition of fines and order of mixing fines were found to influence the fine particle fraction (FPF) significantly. FPF of LDPI formulations using a Rotahaler (Cipla, India) as delivery device at 30, 60 and 90 L/min were found to be 23.1 +/- 1.5 percent and 17.3 +/- 2.2 percent; 25.3 +/- 1.8 percent and 19.6 +/- 1.5 percent and 28.4 +/- 2.1 percent and 22.9 +/- 1.9 percent for AMB1 and AMB2 respectively.
Shah
S P
SP
Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, M. S. University of Baroda, Baroda (Gujarat), India.
Misra
A
A
D000280:Administration, Inhalation; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D005079:Excipients; D008081:Liposomes; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders
D000935:Antifungal Agents; D004337:Drug Carriers; D005079:Excipients; D008081:Liposomes; D011208:Powders; D000666:Amphotericin B